Patients who received placebo in SELECT were randomly assigned ( @:@ ) to receive @ mg or @ mg subcutaneous daclizumab HYP every @ weeks for @ weeks ( treatment initiation group ) ; those who had received daclizumab HYP were randomly assigned ( @:@ ) to continue their present dose with ( washout and re-initiation group ) or without ( continuous treatment group ) a washout period of @ weeks .